Table 1 Characteristics among assessed advanced or metastatic breast cancer breast cancer (A/MBC) patients treated with Eribulin (N=60)

Age (years): Median (IQR)

51 (41 – 59)

Estrogen receptor^a (N=59)

 Positive

34

57.6

 Negative

25

42.4

Progesterone receptor^a (N=58)

 Positive

29

50.0

 Negative

29

50.0

HER2 status^a (N=59)

 Negative

37

62.7

 Positive

22

37.3

Triple negative breast cancer

 No

50

83.3

 Yes

10

16.7

Number of metastatic sites: Median (IQR)

2 (1-3)

Number of metastatic sites:

 <2 sites (0 or 1)

20

33.3

 ≥2 sites

40

66.7

Types of metastasis:

 Non-visceral

24

40.0

 Visceral

27

45.0

 Both visceral and non-visceral

9

15.0

(Neo)adjuvant chemotherapy^a (N=37)

 No

8

21.6

 Yes

29

78.4

Eribulin used line to treat recurrent or metastatic breast cancer: Median (IQR)

4 (3 - 6)

Early-line (First and second line)

15

25.0

Late-line (≥ 3^rd line)

45

75.0

Eribulin duration (days): Median (IQR)

123 (68 – 185)

Eribulin treated

 As monotherapy

46

76.7

 With Trastuzumab (±pertuzumab)

6

10.0

 With Hormone therapy

5

8.3

 With Others^b

3

5.0